Population screening for fetal trisomy 21: Easy access to screening should be balanced against a uniform ultrasound protocol

Prenatal Diagnosis

Volumn 25, Issue 11, 2005, Pages 984-990

  Gyselaers, Wilfried J A ^a   Vereecken, Annie J ^b   Van Herck, Erik J H ^b   Straetmans, Dany P L ^b   De Jonge, Eric T M ^a   Ombelet, Willem U A M ^a   Nijhuis, Jan G ^c  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b Algemeen Medisch Laboratorium   (Belgium)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combined screening; First trimester screening; Nuchal translucency; Population screening; Trisomy 21

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DATA ANALYSIS; EVALUATION; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; MATERNAL SERUM; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; SCREENING TEST; TRISOMY 21;

ADULT; BELGIUM; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; FETAL DISEASES; HUMANS; MASS SCREENING; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, PRENATAL;

EID: 28544434548     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1217     Document Type: Article

References (46)

1. Benn PA. 2002. Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions. Clin Chim Acta 324: 1-11.
2. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 20: 219-225.
3. Borrell A, Casals E, Fortuny A. et al. 2004. First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional study. Prenat Diagn 24: 541-545.
4. Braithwaite JM, Kadir RA, Pepera TA, Morris RW, Thompson PJ, Economides DL. 1996. Nuchal translucency measurement: training of potential examiners. Ultrasound Obstet Gynecol 8: 192-195.
5. Brigatti KW, Malone FD. 2004. First-trimester screening for aneuploidy. Obstet Gynecol Clin North Am 31: 1-20.
6. Christiansen M, Olesen Larsen S. 2002. An increase in cost-effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat Diagn 22: 482-486.
7. Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH. 2003. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Prenat Diagn 23: 306-310.
8. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. 2002. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. BJOG 109: 667-676.
9. De Biasio P, Siccardi M, Volpe G, Famularo L, Santi F, Canini S. 1999. First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy-the combined test. Prenat Diagn 19: 360-363.
10. de Graaf IM, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS, van Lith JM. 1999. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 19: 458-462.
11. de Graaf IM, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, van Lith JM. 2000. Co-variables in first trimester maternal serum screening. Prenat Diagn 20: 186-189.
12. Egan JF, Kaminsky LM, DeRoche ME, Barsoom MJ, Borgida AF, Benn PA. 2002. Antenatal Down syndrome screening in the United States in 2001: a survey of maternal-fetal medicine specialists. Am J Obstet Gynecol 187: 1230-1234.
13. Gyselaers W, De Catte L, Witters I, De Jonge E, Ombelet W, Nijhuis J. 2005. Survey on the future organisation of first trimester ultrasound screening in Flanders, Belgium. Prenat Diagn 25: 518-519.
14. Gyselaers W, Vereecken A, Van Herck E. et al. 2004a. Audit on nuchal translucency thickness measurements in Flanders, Belgium: a plea for methodological standardization. Ultrasound Obstet Gynecol 24: 511-515.
15. Gyselaers W, Vereecken A, Van Herck E. et al. 2004b. Screening for trisomy 21 in Flanders: a 10-years review of 40 490 pregnancies screened by maternal serum. Eur J Obstet Gynecol Reprod Biol 115: 185-189.
16. Haddow JE. 1998. Antenatal screening for Down's syndrome: where are we and where next? Lancet 352: 336-337.
17. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. 1998. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 338: 955-961.
18. Hallahan T, Krantz D, Buchanan P, Larsen JW, Macri J. 2004. Effect of Ethnicity of First-trimester Down Syndrome Screening, http://genetics.faseb.org/ genetics/ashg00/f2365.htm, (accessed 205/2004).
19. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr., Macri JN. 2000. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 96: 207-213.
20. Logghe H, Cuckle H, Sehmi I. 2003. Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. Prenat Diagn 23: 389-392.
21. Malone FD, D'Alton ME. 2003. First-trimester sonographic screening for Down syndrome. Obstet Gynecol 102: 1066-1079.
22. Morris JK, Wald NJ, Watt HC. 1999. Fetal loss in Down syndrome pregnancies. Prenat Diagn 19: 142-145.
23. Morris JK, Mutton D, Alberman E. 2002a. Potential biases in Down syndrome birth prevalence estimation (author's reply). J Med Screen 9: 192.
24. Morris JK, Mutton DE, Alberman E. 2002b. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 9: 2-6.
25. Muller F, Aegerter P, Ngo S. et al. 1999. Software for prenatal down syndrome risk calculation: a comparative study of six software packages. Clin Chem 45: 1278-1280.
26. Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. 2003. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn 23: 833-836.
27. Nicolaides KH, Heath V, Cicero S. 2002. Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 22: 308-315.
28. Niemimaa M. 2003. First Trimester Screening for Down Syndrome. Thesis, University of Oulu, Finland; 1-62.
29. Onda T, Tanaka T, Takeda O. et al. 1998. Agreement between predicted risk and prevalence of Down syndrome in second-trimester triple-marker screening in Japan. Prenat Diagn 18: 956-958.
30. Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN. 1997. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 10: 381-386.
31. Reynolds T, Penney M. 1989. The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 27: 452-458.
32. Schuchter K, Hafner E, Stangl G, Metzenbauer M, Hofinger D, Philipp K. 2002. The first trimester 'combined test' for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 22: 211-215.
33. Scott F, Peters H, Bonifacio M. et al. 2004. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Aust N Z J Obstet Gynaecol 44: 205-209.
34. Snijders RJ, Thom EA, Zachary JM. et al. 2002. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 19: 353-359.
35. Spencer K. 2000. Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 20: 91-95.
36. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 110: 281-286.
37. Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM. 2004. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 24: 774-780.
38. von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M. et al. 2002. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. J Matern Fetal Neonatal Med 12: 89-94.
39. Wald N. 2003. Certification of competence in performing specific procedures or tests in screening practice. Prenat Diagn 23: 861.
40. Wald N, Cuckle H, Densem J. et al. 1988. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 297: 883-887.
41. Wald NJ, Kennard A, Hackshaw A, McGuire A. 1997. Antenatal screening for Down's syndrome. J Med Screen 4: 181-246.
42. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10: 56-104.
43. Wapner R, Thom E, Simpson JL. et al. 2003. First-trimester screening for trisomies 21 and 18. N Engl J Med 349: 1405-1413.
44. Welch KK, Malone FD. 2003. Nuchal translucency-based screening. Clin Obstet Gynecol 46: 909-922.
45. Whittle M. 2001. Down's syndrome screening: where to now? BJOG 108: 559-561.
46. Wojdemann KR, Christiansen M, Sundberg K, Larsen SO, Shalmi A, Tabor A. 2001. Quality assessment in prospective nuchal translucency screening for Down syndrome. Ultrasound Obstet Gynecol 18: 641-644.